Home
HelpMayo Test ID THSIF Thrombospondin Type 1 Domain Containing 7A (THSD7A), Immunofluorescence
Ordering Guidance
If additional interpretation/analysis is needed, request PATHC / Pathology Consultation along with this test and send the corresponding renal pathology light microscopy and immunofluorescence (IF) slides (or IF images on a CD), electron microscopy images (prints or CD), and the pathology report.
Necessary Information
A preliminary pathology report is required for testing to be performed. Send information with specimen. The laboratory will not reject testing if a reason for testing is not provided; however appropriate testing and interpretation may be compromised or delayed. If not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Required
Specimen Type: Kidney tissue
Preferred: 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; paraffin sections 3 to 4-microns thick
Acceptable: Formalin-fixed, paraffin-embedded (FFPE) kidney tissue block
Useful For
Diagnosis of thrombospondin type 1 domain-containing 7A (THSD7A)-associated membranous nephropathy
Method Name
Direct Immunofluorescence (DIF)
Reporting Name
THSD7A ImmunofluorescenceSpecimen Type
SpecialSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Frozen | |||
| Refrigerated | |||
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Thrombospondin type 1 domain-containing 7A (THSD7A) is a target antigen in membranous nephropathy (MN) and is detected in approximately 3% to 5% of non- phospholipase A2 receptor (PLA2R)-associated MN patients. Differentiating THSD7A-associated MN from PLA2R-associated MN is critical as approximately 20% of patients with THSD7A-associated MN have solid malignancy suggesting that THSD7A-associated MN is more likely to be secondary to malignancy than PLA2R-associated MN.
Interpretation
Staining is interpreted and reported as negative or positive.
Cautions
No significant cautionary statements
Clinical Reference
1. Hoxha E, Beck Jr LH, Wiech T et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28:520-531
2. Larsen CP, Cossey LN, Bech LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol. 2016;29:421-426
3. Sharma SG, Larsen CP: Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-622
Method Description
Direct immunofluorescence staining on sections of formalin-fixed, paraffin-embedded kidney tissue.(Unpublished Mayo method)
Specimen Retention Time
Until reportedPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88346-Primary IF
88350-If additional IF
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| THSIF | THSD7A Immunofluorescence | 101116-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 605245 | Interpretation | 50595-8 |
| 606383 | Participated in the Interpretation | No LOINC Needed |
| 606384 | Report electronically signed by | 19139-5 |
| 606385 | Addendum | 35265-8 |
| 606386 | Gross Description | 22634-0 |
| 606387 | Material Received | 22633-2 |
| 606388 | Disclaimer | 62364-5 |
| 606389 | Case Number | 80398-1 |
Specimen Minimum Volume
See Specimen Required
Day(s) Performed
Monday through Friday